Syros Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Syros Pharmaceuticals

14/11/2022 14:32

* Syros Pharmaceuticals Inc  SYRS.OQ  reported a quarterly
adjusted loss of $3.21​​ per share for the quarter ended in
September. The mean expectation of six analysts for the quarter
was for a loss of $4.01 per share.
    * Revenue fell 31.7% to $3.89 million from a year ago;
analysts
expected $5.23 million. 
    * Syros Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $3.21​.
    * The mean earnings estimate of analysts had risen by
about 11.3%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Syros Pharmaceuticals Inc shares had fallen by 38.2% this
quarter and lost 87.8% so far this year.
    * The company reported a quarterly loss of $30.25 million.
    * Wall Street's median 12-month price target for Syros
Pharmaceuticals Inc is $40.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
14 at 02:31 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -4.01          -3.21          Beat
 Jun. 30 2022      -4.08          -5.40          Missed
 Mar. 31 2022      -4.70          -4.00          Beat
 Dec. 31 2021      -4.66          -3.80          Beat